A Phase II, Single-arm Study to Evaluate the Efficacy and Safety of Inavolisib in Combination With Eribulin in Pretreated Advanced Triple-negative Breast Cancer Harboring a PIK3CA Mutation

Inclusion Criteria: * Patients must meet the following criteria for study entry: * Signed Informed Consent Form * Female participants who are at least 18 years of age on the day of signing informed consent * Evaluable or measurable disease per RECIST v1.1 * Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 * Life expectancy of \> 12 weeks * Adequate hematologic and organ function within 14 days prior to initiation of study treatment, defined by the following: * Absolute neutrophil count ≥ 1500/μL * Hemoglobin ≥ 9 g/dL * Platelet count ≥ 100,000/μL * Fasting glucose \< 126 mg/dL or \< 7 mmol/L and glycosylated hemoglobin (HbA1C) \< 6.5% or \< 48 mmol/mol * Total bilirubin ≤ 1.5 × upper limit of normal (ULN) (\< 3 × ULN if Gilbert's disease) * Serum albumin ≥ 2.5 g/dL or 25 g/L * AST and ALT ≤ 2.5 × ULN with the following exception: * Patients with documented liver metastases: AST and ALT ≤ 5.0 × ULN o ALP ≤ 2.5 × ULN with the following exception: * Participants with documented liver or bone metastases: ALP ≤ 5.0 × ULN o INR \< 1.5 × ULN and aPTT \< 1.5 × ULN * For participants requiring anticoagulation therapy with warfarin or similar agents (such as Vitamin K antagonists), a stable INR between 2 and 3 is required. If anticoagulation is required for a prosthetic heart valve, then stable INR between 2.5 and 3.5 is permitted. * Creatinine clearance ≥ 60 mL/min on the basis of the Cockcroft-Gault glomerular …